menu
    • menu

    Company profile for Curasight

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types, most notably for risk stratification in prostate cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CurasightDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Ole Maaløes Vej 3 DK-2200 København N
    Telephone
    Telephone
    +45 22 83 01 60
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.curasight.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curasight To Present At TD Cowen Health Care Conference
    Curasight To Present At TD Cowen Health Care Conference

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston-302689307.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    Curasight Unveils Strong uTREAT Data for High-Grade Gliomas
    Curasight Unveils Strong uTREAT Data for High-Grade Gliomas

    12 Jan 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas-302658794.html

    PR NEWSWIRE BIO
    12 Jan 2026
    Share Share
    Curasight Initiates Phase 1 Trial For Utreat In Brain Cancer
    Curasight Initiates Phase 1 Trial For Utreat In Brain Cancer

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-announces-successful-dosing-of-first-patient-in-phase-1-trial-with-utreat-in-brain-cancer-302646271.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Curasight Opens Enrollment in uTREAT Phase 1 Brain Cancer Trial
    Curasight Opens Enrollment in uTREAT Phase 1 Brain Cancer Trial

    26 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasights-utreat-phase-1-trial-in-brain-cancer-now-open-for-patient-enrollment-302626494.html

    PR NEWSWIRE
    26 Nov 2025
    Share Share
    Curasight Gets CTA Nod for Ph1 uTREAT Trial in Brain Cancer
    Curasight Gets CTA Nod for Ph1 uTREAT Trial in Brain Cancer

    26 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients-302538481.html

    PR NEWSWIRE
    26 Aug 2025
    Share Share
    Curasight A/S Achieves First Milestone under collaboration with Curium Inc.
    Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

    22 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc-302040336.html

    PR NEWSWIRE
    22 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search